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COL4A2 Mutations Impair COL4A1 and COL4A2
Secretion and Cause Hemorrhagic Stroke
Marion Jeanne,1 Cassandre Labelle-Dumais,1 Jeff Jorgensen,1W. Berkeley Kauffman,1 Grazia M. Mancini,2
Jack Favor,3 Valerie Valant,4,5,6 Steven M. Greenberg,4 Jonathan Rosand,4,5,6 and Douglas B. Gould1,*
Collagen, type IV, alpha 1 (COL4A1) and alpha 2 (COL4A2) form heterotrimers and are abundant components of basement membranes,
including those of the cerebral vasculature. COL4A1mutations are an increasingly recognized cause of multisystem disorders, including
highly penetrant cerebrovascular disease and intracerebral hemorrhage (ICH). Because COL4A1 and COL4A2 are structurally and func-
tionally associated, we hypothesized that variants in COL4A2 would also cause ICH. We sequence COL4A2 in 96 patients with ICH and
identify three rare, nonsynonymous coding variants in four patients that are not present in a cohort of 144 ICH-free individuals. All
three variants change evolutionarily conserved amino acids. Using a cellular assay, we show that these putative mutations cause
intracellular accumulation of COL4A1 and COL4A2 at the expense of their secretion, which supports their pathogenecity. Furthermore,
we show that Col4a2 mutant mice also have completely penetrant ICH and that mutations in mouse and human lead to retention of
COL4A1 andCOL4A2within the endoplasmic reticulum (ER). Importantly, two of the three putativemutations found in patients trigger
ER stress and activate the unfolded protein response. The identification of putative COL4A2mutations that might contribute to ICH in
human patients provides insight into the pathogenic mechanisms of this disease. Our data suggest that COL4A2 mutations impair
COL4A1 and COL4A2 secretion and can also result in cytotoxicity. Finally, our findings suggest that, collectively, mutations in
COL4A1 and COL4A2 contribute to sporadic cases of ICH.Strokes are common and devastating neurological events
with poor clinical outcomes for which effective treatment
is limited. This is especially true for intracerebral hemor-
rhages (ICHs), which are associated with the highest rate
of mortality despite only accounting for 10–15% of all
strokes.1 Up to 50% of individuals die within the first
year following ICH, and the majority of survivors suffer
life-long disability.2 Prevention is therefore of central
importance for reducing the personal and societal burden
of ICH. Determining the genetic factors leading to cerebro-
vascular diseases allows identification of individuals who
are at greater risk of developing ICH and for whom preven-
tative interventions might be efficacious. Additionally,
identifying causative or predisposing genetic risk factors
facilitates understanding of the biological mechanisms
underlying disease. Although sporadic ICH is often associ-
ated with cerebral amyloid angiopathy (CAA) or hyperten-
sive vasculopathy, the precipitating events leading to
hemorrhage are poorly defined.
Using genetic screens in mice and candidate gene
approaches in humans, we showed that mutations in the
gene coding for collagen, type IV, alpha 1 (COL4A1 [MIM
120130]) cause porencephaly (MIM 175780) and multi-
system small vessel disease (MIM 607595), including
nephropathy and ICH.3,4 Col4a1mutant mice had a broad
spectrum of cerebrovascular diseases, including pre- and
perinatal ICH, porencephalic cavities, progressive, multi-
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The Amehemorrhages.3,4 Dominant COL4A1 mutations are being
increasingly recognized as an important cause of highly
penetrant cerebrovascular diseases, including porence-
phaly and ICH.3–15 COL4A1 mutations in mice and
humans are pleiotropic and can affect multiple organ
systems with different levels of severity. Using controlled
genetic approaches in mice, we have shown that at least
some of the variability in the penetrance and severity of
Col4a1-induced pathology can be attributed to environ-
mental influences and to genetic context.3,16,17 Accumu-
lating evidence suggests that allelic heterogeneity might
also contribute to variable expressivity of COL4A1 muta-
tions. A subset of individuals with COL4A1 mutations are
reported to have a distinct clinical phenotype referred to
as hereditary angiopathy, nephropathy, aneurysms, and
cramps syndrome (HANAC [MIM 611773]), and the muta-
tions in these individuals cluster within a 31 amino acid
region of the COL4A1 protein that encompasses integrin
binding sites.8,12,18,19 These data suggest that alterations
of specific functional domains could contribute to the
phenotypic variability associated with COL4A1mutations.
COL4A1 forms heterotrimers with COL4A2 (MIM
120090) and, together, they are the most abundant and
prevalent proteins in basement membranes, including
those of the cerebral vasculature. Heterotrimers composed
of one COL4A2 and two COL4A1 peptides are assembled
and modified within the endoplasmic reticulum (ER)
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Table 1. Inclusion and Exclusion Criteria
Patient Control
Inclusion Criteria
either gender either gender
ability and willingness to consent ability and willingness
to consent
symptomatic intracerebral hemorrhage
Exclusion Criteria
antecedent head trauma history of intracerebral
hemorrhage
ischemic stroke during 2 weeks prior
to intracerebral hemorrhage
intracerebral tumor
intracerebral tumor arteriovenous malformation,
aneurysm, or central nervous
system vasculitis
arteriovenous malformation,
aneurysm, or central nervous
system vasculitis
primary coagulopathy,
blood dyscrasia, or active
liver disorder
primary coagulopathy, blood
dyscrasia, or active liver disorder
use of cocaine or
sympathomimetic drug
use of cocaine or
sympathomimetic drug
alcohol abuse
alcohol abuseinto vesicles for secretion into the vascular basement
membranes.20–22 In the extracellular space, heterotrimers
polymerize into flexible sheets, which not only provide
strength to basement membranes but also participate in
dynamic biological processes through interactions with
growth factors and cell surface receptors, including integ-
rins.23–26
At the carboxy terminus of COL4A1 and COL4A2 is
a globular noncollagenous (NC1) domain responsible for
initiating heterotrimer formation within the ER.27 A 7S
domain that is involved in lateral intertrimer associations
in the extracellular matrix is present at the amino terminus
of both proteins. Flanked by these terminal domains are
the large triple-helix-forming domains that constitute
more than 80% of both the COL4A1 and COL4A2
proteins. The triple-helix-forming domain is characteristic
of collagens and is composed of repeating Gly-Xaa-Yaa
amino acid residues where there is a requirement for
a glycine every third amino acid and where the X and Y
amino acids are often proline or lysine residues that
undergo posttranslational processing in order to crosslink
the constituent peptides of a heterotrimer.28,29 The triple-
helix-forming domains of type IV collagens also contain
frequent and positionally conserved interruptions within
the Gly-Xaa-Yaa repeats, which are thought to confer
molecular flexibility to type IV collagens. Pathogenic
mutations are reported in the NC1 domain, however, the
vast majority of disease-causing mutations reported to
date for various types of collagens, including type IV colla-
gens, have been shown to interfere with triple-helix forma-
tion or stability.30
Because of the intimate structural and functional associ-
ation between COL4A1 and COL4A2 and because of the
presumed mechanisms by which COL4A1 mutations lead
to disease, we expect that COL4A2 mutations will cause
pathologies similar to those resulting from COL4A1 muta-
tions. In support of this hypothesis, mutations in COL4A2
orthologs phenocopy mutations in COL4A1 orthologs in
mice and in Caenorhabditis elegans.31–34 However, to date,
pathogenic COL4A2 mutations have not been reported
in humans. To test the hypothesis that COL4A2mutations
cause ICH, we sequenced COL4A2 in a large cohort of unre-
lated individuals diagnosed with sporadic hemorrhages
not related to arteriovenous malformations, tumors, or
impaired coagulation. We identified putative pathogenic
variants in four out of 96 people, showed that COL4A2
proteins are sequestered within the ER, and, in some cases,
caused activation of the unfolded protein response (UPR).
For the affected cohort, we selected 96 individuals from
among 800 consecutive participants with ICH presenting
to Massachusetts General Hospital.35 Cranial computed
tomography scans and/or magnetic resonance images of
the head were completed for all individuals, and hemor-
rhages were classified according to the Boston Criteria.36
For the present study, 48 individuals with probable CAA-
related ICH and 48 individuals with presumed hyper-
tension-related deep ICH were chosen according to the92 The American Journal of Human Genetics 90, 91–101, January 13,inclusion and exclusion criteria published previously36
(summarized in Table 1). Simultaneously, we collected
DNA from ethnically and age-matched individuals who
were free of a history of hemorrhagic stroke and were
drawn from the primary care practices at Massachusetts
General Hospital. All participants or their surrogates
provided informed consent for study participation and
the Massachusetts General Hospital institutional review
board approved all study procedures.
We performed direct sequence analysis (ABI BigDye
v3.1) of the entire coding sequence of COL4A2 including
the flanking intronic regions (more than 50 nucleotides
for most introns and never less than 20 nucleotides)
by using 42 pairs of primers (Table S1, available online).
Using Sequencher software (Gene Codes Corporation),
we identified 168 sequence variants of which 137 were in-
tronic (Table S2). Because we expected that pathogenic
mutations having a strong effect will be rare, nonsynony-
mous variants, we focused our attention on these. It is
possible that intronic or synonymous variants are patho-
genic, in which case our estimation of the role of
COL4A2 in ICH would be understated. Of the 31 coding
variants, ten were nonsynonymous (Table 2). Four nonsy-
nonymous variants, c.1550G>A, c.2048G>C, c.2152C>T,
and c.4195G>A, were found at high frequency and consid-
ered unlikely to be causative mutations (p.Arg517Lys,
p.Gly683Ala, p.Pro718Ser, and p.Val1399Ile, hereafter
referred to as COL4A2R517K, COL4A2G683A, COL4A2P718S
andCOL4A2V1399I, respectively).Notably, oneof these vari-
ants changes a glycine residue, and glycine missense2012
Table 2. Coding SNPs Identified
Variant Patients Controls
Exon DNA Protein
Homozygous
Major
Hetero-
zygous
Homozygous
Minor Total
Homozygous
Major
Hetero-
zygous
Homozygous
Minor Total
Nonsynonymous
9 c.574G>T p.Val192Phe V192F G/G (91) G/T (1) T/T (0) 92 G/G (144) G/T (0) T/T (0) 144
22 c.1550G>A p.Arg517Lys R517K A/A (33) A/G (45) G/G (15) 93
27 c.2048G>C p.Gly683Ala G683A G/G (71) G/C (17) C/C (4) 92
28 c.2102A>G p.Lys701Arg K701R A/A (94) A/G (1) G/G (0) 95 A/A (137) A/G (0) G/G (0) 137
28 c.2152C>T p.Pro718Ser P718S C/C (57) C/T (27) T/T (11) 95 C/C (92) C/T (41) T/T (4) 137
36 c.3326G>A p.Arg1109Gln R1109Q G/G (92) G/A (1) A/A (1) 94 G/G (132) G/A (1) A/A (0) 133
37 c.3368A>G p.Glu1123Gly E1123G A/A (91) A/G (2) G/G (0) 93 A/A (142) A/G (0) G/G (0) 142
37 c.3448C>A p.Gln1150Lys Q1150K C/C (92) C/A (1) A/A (0) 93 C/C (142) C/A (0) A/A (0) 142
44 c.4195G>A p.Val1399Ile V1399I G/G (86) G/A (8) A/A (0) 94
48 c.5068G>A p.Ala1690Thr A1690T G/G (92) G/A (1) A/A (0) 93 G/G (143) G/A (0) A/A (0) 143
Synonymous
3 c.49C>T p.Leu17Leu L17L C/C (91) C/T (1) T/T (0) 92
5 c.297A>G p.Thr99Thr T99T A/A (91) A/G (2) G/G (0) 93
10 c.594C>T p.Pro198Pro P198P C/C (92) C/T (1) T/T (0) 93
17 c.1008C>T p.Pro336Pro P336P C/C (26) C/T (48) T/T (17) 91 C/C (30) C/T (68) T/T (38) 136
17 c.1011G>A p.Lys337Lys K337K G/G (92) G/A (1) A/A (0) 93 G/G (135) G/A (1) A/A (0) 136
19 c.1095G>A p.Pro365Pro P365P G/G (86) G/A (0) A/A (8) 94
19 c.1179C>T p.Ile393Ile I393I C/C (82) C/T (2) T/T (10) 94
20 c.1308C>T p.Pro436Pro P436P C/C (92) C/T (1) T/T (0) 93
22 c.1488G>A p.Pro496Pro P496P A/A (33) A/G (44) G/G (16) 93
34 c.3204C>T p.Ser1068Ser S1068S C/C (91) C/T (1) T/T (0) 92
41 c.3804A>T p.Pro1268Pro P1268P A/A (88) A/T (4) T/T (0) 92
41 c.3807T>C p.Gly1269Gly G1269G T/T (88) T/C (4) C/C (0) 92
41 c.3876C>T p.Leu1292Leu L1292L C/C (91) C/T (1) T/T (0) 92
43 c.4083T>C p.Thr1361Thr T1361T T/T (89) T/C (3) C/C (0) 92
43 c.4089G>A p.Ala1363Ala A1363A G/G (61) G/A (25) A/A (6) 92
45 c.4292T>C p.Phe1430Phe F1430F T/T (90) T/C (4) C/C (0) 94
46 c.4428G>A p.Pro1476Pro P1476P G/G (92) G/A (1) A/A (0) 93
46 c.4515A>G p.Pro1505Pro P1505P G/G (63) G/A (28) A/A (2) 93
47 c.4617G>A p.Ala1539Ala A1539A G/G (78) G/A (15) A/A (0) 93
47 c.4737C>T p.Ala1579Ala A1579A C/C (92) C/T (1) T/T (0) 93
48 c.4929G>A p.Pro1643Pro P1643P G/G (92) G/A (1) A/A (0) 93 G/G (141) G/A (2) A/A (0) 143mutations within the triple-helix domain constitute the
prototypic pathogenic mutation for several types of colla-
gens. However, this variant, COL4A2G683A, is highly poly-
morphic (17 out of 92 affected individuals were heterozy-
gous and 4 out of 92 were homozygous for the minor
allele) and impacts a glycine that is part of a repeat interrup-
tion and not part of the Gly-Xaa-Yaa tripeptide repeat
pattern necessary for triple-helix formation. Thus, out ofThe Amea cohort of 96 individuals, we identified six nonsynony-
mous rare variants that we deemed to be potentially patho-
genic (Figure 1A).
We resequenced at least 264 control chromosomes for
each exon in which one of the six nonsynonymous vari-
ants was found (Table 2). One variant, c.3326G>A
([p.Arg1109Gln] hereafter referred to as COL4A2R1109Q),
was identified in two affected individuals (including onerican Journal of Human Genetics 90, 91–101, January 13, 2012 93
Figure 1. Six Nonsynonymous Rare Variants Identified in Patients Result in Missense Changes in Amino Acids that Are Highly
Conserved across Species
(A) Electropherograms of genomic DNA from patients (top panels) or control individuals (lower panels) showing coding variants in
patients.
(B) Multispecies alignment of COL4A2 orthologs shows that most of the rare coding variants identified in patients change highly
conserved amino acids.homozygote) and in a single control individual, suggesting
that this variant might not be pathogenic and other vari-
ants were present in dbSNP. However, because reduced
penetrance is documented in COL4A1 mutations and
because genetic context dependency has been demon-
strated for Col4a1 mutations in mice, we chose to include
these variants for further analysis.
We performed multispecies alignments to determine
whether the affected amino acids were conserved and
whether there was precedence for any of the variants in
other species (Figure 1B). Five of the six variants were
highly conserved across species and perfectly conserved
among mammals. COL4A2R1109Q was less conserved and,
in fact, Rhesus monkey (Macaca mulatta) has a glutamine
(Q) at this position of its COL4A2 ortholog, further sug-
gesting that this variant might not be pathogenic. We
then used commonly referenced algorithms to help predict
the potential impact of each variant. The automated
tools SIFT (Sorting Intolerant from Tolerant, version 2.0)
and PolyPhen (Polymorphism Phenotyping-2) lead to
different and even contradictory results. The evolu-
tionary-based approach, SIFT, predicted only one damag-
ing variant (c.574G>T [p.Val192Phe], hereafter referred
to as COL4A2V192F), whereas the structure- and evolu-
tionary-based approach, PolyPhen, predicted two differ-
ent variants to be possibly damaging (c.3448C>A
[p.Gln1150Lys] and c.5068G>A [ p.Ala1690Thr]; hereafter
referred to as COL4A2Q1150K and COL4A2A1690T) and one
different variant to be probably damaging (c.3368A>G
[p.Glu1123Gly]; hereafter referred to as COL4A2E1123G).
However, PolyPhen also predicted the COL4A2P718S
variant to be possibly damaging despite this variant being
highly polymorphic and found in both cohorts at high
frequencies and therefore highly unlikely to be patho-94 The American Journal of Human Genetics 90, 91–101, January 13,genic. Based on these results, we contend that in silico
approaches are currently unlikely to accurately predict
functional consequences of COL4A2 variants.
Therefore, to evaluate the functional consequences of
putative COL4A2 mutations, we used a cell-culture-based
assay that we have previously validated for COL4A1muta-
tions.17 Pathogenic mutations in genes coding for several
types of collagen often disrupt normal heterotrimer forma-
tion leading to intracellular accumulation of misfolded
proteins and decreased heterotrimer secretion. Thus, we
used an in vitro secretion assay to test whether rare
COL4A2 variants changed the ratio of extracellular to
intracellular COL4A2 and COL4A1 proteins in cultured
cells. As described previously,17 we transfected HT1080
cells (which endogenously express COL4A1 and COL4A2)
with a control COL4A2 cDNA (NM_001846.2) or with
COL4A2 cDNA that contained one of the six nonsynony-
mous rare sequence variants. At 80%–90% confluence,
cells were serum deprived and treated with ascorbic acid
(50 mg/ml), and after 24 hr the conditioned medium was
collected and cells were lysed for subsequent immunoblot
analysis with rat COL4A1 (H11) or rat COL4A2 (H22)
monoclonal antibody (1:100 and 1:200, respectively;
Shigei Medical Research Institute, Japan). Densitometric
analysis was performed on low-exposure images with Im-
ageJ software (National Institutes of Health) and compar-
ison of values was carried out with Student’s t test with
p < 0.05 considered as statistically significant. The extra-
cellular to intracellular ratios of COL4A2 and COL4A1
obtained from cells transfected with each of the variants
were expressed relative to the ratio obtained from cells
transfected with the control COL4A2. As controls for the
functional assay, we also tested a pathogenic mutation
(c.4165G>A [p.Gly1389Arg] referred to as COL4A2G1389R)2012
Figure 2. Functional Assay Reveals that COL4A2E1123G, COL4A2Q1150K, and COL4A2A1690T Impair COL4A2 and COL4A1 Secretion
Ratios of extracellular to intracellular COL4A2 (A) or COL4A1 (B) from cells expressing different COL4A2 alleles were determined by
immunoblot analysis and are expressed as a percent relative to control (NM_001846.2) COL4A2 cDNA (mean of five independent exper-
iments5 standard error of themean [SEM]). The highly polymorphic common variant COL4A2P718S was used as a presumptive negative
control, and the pathogenic mutation COL4A2G1389R was used as a positive control of the functional assay. The variants COL4A2V192F,
COL4A2K701R, or COL4A2R1109Q have no functional consequences on the biosynthesis of COL4A1/COL4A2 heterotrimers. The
COL4A2E1123G, COL4A2Q1150K, and COL4A2A1690T variants significantly reduce the extracellular to intracellular ratio of COL4A2
and COL4A1, suggesting that they are pathogenic mutations (*p < 0.05, **p < 0.01). The control cDNA and a common polymorphism
are shown in light gray, the known pathogenic variant is shown in black, and the rare variants identified in the patient cohort are shown
in dark gray.that causes familial porencephaly and small-vessel disease
(data not shown) and the highly polymorphic common
variant (COL4A2P718S) that is expected to have no impact
on COL4A2 biosynthesis. As predicted, cells expressing
the validated mutation had significantly decreased extra-
cellular to intracellular ratio of COL4A2, whereas cells
expressing the common polymorphism did not differ
significantly from cells transfected with the control
cDNA (Figure 2A). Using the same assay, we found that
three variants identified only in the affected cohort had
significant reduction in the ratio of extracellular to intra-
cellular COL4A2 and three did not (Figure 2A). Because
COL4A1 and COL4A2 are secreted as heterotrimers, we
also determined the extracellular to intracellular levels of
COL4A1 and found that the results correlated perfectly
in that the positive control and the same three rare variants
all showed significant decreases in the extracellular to
intracellular ratio (Figure 2B). COL4A2R1109Q, which was
present in one control individual and is also present in
M. mulatta, was among the three variants that did not
have an effect on COL4A2 and COL4A1 secretion. These
results strengthen the suggestion that COL4A2P718S and
COL4A2R1109Q are not pathogenic and also suggest that
COL4A2V192F and c.2102A>G ([p.Lys701Arg] referred to
as COL4A2K701R) are not pathogenic. Importantly, our
assay showed that COL4A2E1123G, COL4A2Q1150K, and
COL4A2A1690T variants have functional consequences as
they interfere with proper secretion of COL4A2 and
COL4A1 and therefore constitute putative pathogenic
mutations.
The COL4A2E1123G variant was identified in two affected
individuals and was not found in 142 ethnically matchedThe Amecontrol individuals. The first individual was a 72-year-old
white non-Hispanic man with probable CAA-related ICH
in the right occipital lobe. He has no family history of
ICH and was not taking aspirin or an anticoagulant at
the time of his hemorrhage. The second was a 72-year-
old white non-Hispanic woman with a history of hyper-
tension who developed hemorrhage in the left basal
ganglia while taking aspirin. There was no family history
of ICH. These two individuals had adenine to guanine
transitions (c.3368A>G) in exon 37, leading to glutamate
to glycine substitutions in the X-position amino acid of
a Gly-Xaa-Yaa repeat within the triple-helix-forming
domain of the COL4A2 protein.
The COL4A2Q1150K variant was found in one affected
individual but not in the control cohort. The affected indi-
vidual was a 45-year-old white Hispanicmanwith a history
of hypertension who developed hemorrhage in the left
basal ganglia. He was not taking aspirin or anticoagulant
at the time of his hemorrhage. Notably, two sisters of this
individual had ICH. At the time of subject enrollment,
both sisters were over age 40 and had no history of
dementia; however, the familymembers were not available
for follow-up. The variant was a cytosine to adenine trans-
version (c.3448C>A) in exon 37, leading to a glutamine to
lysine replacement in the X-position of a Gly-Xaa-Yaa
repeat.
The third variant, COL4A2A1690T, was identified in one
individual but none of the controls and was not a known
variant. The individual was a 69-year-old African American
man with probable CAA-related ICH in the right occipital
lobe. He was not taking aspirin or anticoagulant at the
time of his hemorrhage. There was no family history ofrican Journal of Human Genetics 90, 91–101, January 13, 2012 95
ICH. He had a guanine to adenine transition (c.5068G>A)
in exon 48 leading to an alanine to threonine substitution.
Unlike the previous mutations, which occur in the triple-
helix-forming domain, amino acid 1690 is close to the
C terminus and is located in the globular NC1 domain of
the protein (which does not participate in triple-helix
formation).
In mice, Col4a2 mutations were reported to cause
prenatal focal ICHs in six out of 11 embryos between
embryonic day (E) E15 and E17, and so we sought to deter-
mine whether adult Col4a2 mutant mice also have ICH.31
We have previously shown that phenotypes in Col4a1
mutant mice are genetic-context dependent; therefore,
we bred the mouse p.Gly646Asp (COL4A2G646D) mutation
onto a uniform genetic background by iteratively
crossing to C57BL/6J mice for at least seven generations.
Col4a2þ/þ and Col4a2þ/G646D mice were aged to 7.5 to
9.5 months and then tested for the presence of ICH
by staining with Prussian Blue as described previously.3
ICH were never observed in control mice (n ¼ 7) however,
we found that all mutant mice (n ¼ 5) had multifocal
ICHs in the subcortical region of the forebrain and in
the cerebellum (Figure 3A). We quantified the extent
of ICH by measuring the percentage of the cross sectional
area that stained with Prussian blue and compared it to
the extent of ICH in the brains of mice with a severe
mutation in Col4a1.3,4,16 Compared to Col4a1þ/Dex40
mutant mice, ICH in Col4a2þ/G646D mice was consistently
much less severe (Figure 3B). One interpretation is that
Col4a2 mutations lead to a less severe phenotype
than Col4a1 mutations. This explanation could be
rationalized by the fact that COL4A1/A2 heterotrimers
have a 2:1 ratio of COL4A1:COL4A2. Thus, in heterozy-
gous Col4a1 mutants, 75% of the heterotrimers would
have at least one mutant COL4A1 peptide, whereas in
heterozygous Col4a2 mutants only 50% of the hetero-
trimers would be expected to contain a mutant COL4A2
peptide (assuming that normal and mutant peptides
participate equally in heterotrimer formation). Although
this interpretation is possible it is inconsistent with obser-
vations of mild ICH in mice with other Col4a1 mutant
alleles, which can also be much milder than the pheno-
type of Col4a1þ/Dex40 mutant mice (data not shown).
These data support that both intergenic and intragenic
allelic heterogeneity influence variable expressivity,
however, their relative contributions remain to be
determined.
To test whether the mouse Col4a2þ/G646D mutation also
led to intracellular accumulation of COL4A1 and COL4A2
proteins at the expense of their secretion we isolated and
cultured mouse embryonic fibroblasts (MEFs) from E14.5
embryos. Western analysis showed diminished secretion
and increased intracellular accumulation (data not
shown). Further, immunolabeling of cultured MEFs from
control C57BL/6J mice with anti-COL4A1 or anti-
COL4A2 revealed colocalization of COL4A1/A2 hetero-
trimers with protein disulphide isomerase (PDI; ER resi-96 The American Journal of Human Genetics 90, 91–101, January 13,dent protein necessary for collagen biosynthesis) but also
presence of COL4A1/A2 heterotrimers in secretory
vesicles (Figures 3C and 3D). In contrast, in MEFs derived
from Col4a2þ/G646D embryos, there is less COL4A1 and
COL4A2 undergoing secretion, and instead there is an
increase in the intensity of COL4A1 and COL4A2 labeling
in the ER. The results for Col4a2þ/G646D, although less
severe, are consistent with the results for Col4a1þ/Dex40
mutant mice and suggest that ER retention of mutant
proteins underlies diminished secretion.
Next, we sought to determine whether the reduction in
extracellular to intracellular ratio of the three putative
COL4A2 mutations that we found in the ICH cohort
were also a consequence of increased retention in the ER.
We transfected COL4A2 cDNA into HT1080 cells, HeLa
cells or MEFs, and all cell types revealed similar results.
In each case, cells expressing the control cDNA, the
common polymorphism (COL4A2P718S) or the three likely
nonpathogenic variants (COL4A2V192F, COL4A2K701R and
COL4A2R1109Q) had COL4A2 immunolabeling in both
the ER, where it colocalized with PDI, and in secretory vesi-
cles being trafficked from the ER toward the plasma
membrane (Figure 4A, arrow, and data not shown). In
contrast, the expression of either the validated pathogenic
variant (COL4A2G1389R) or the three putative mutations
(COL4A2E1123G, COL4A2Q1150K, and COL4A2A1690T) re-
sulted in increased colocalization with PDI and absence
of COL4A2 in secretory vesicles and confirm that the
reduction in extracellular to intracellular COL4A1 and
COL4A2 ratios is the consequence of retention within
the ER.
Intracellular accumulation of mutant proteins can lead
to ER stress and activation of the unfolded protein
response (UPR) in Col4a1 mutant mice.16,37 To investigate
whether putative COL4A2 mutations might also lead to
activation of these same pathways, we performed quantita-
tive RT-PCR (qPCR) to determine the expression levels of
multiple ER stress markers and UPR effectors in cells stably
transfected with control COL4A2 cDNA or COL4A2 cDNA
containing the various variants. We generated multiple
clones of HT1080 cells that stably expressed control
COL4A2 cDNA or variant COL4A2 cDNA and we selected
four independent clones for each allele that had similar
COL4A2 expression levels. We first confirmed that there
were no significant differences in the level of COL4A1
expression or the level of expression of the collagen-
binding chaperone HSP47 (Figure 5). To test for the
presence of ER stress or for the activation of the UPR, we
performed qPCR for the ER resident chaperone BiP, two
ER-resident UPR transducers PERK and ATF6, a UPR-acti-
vated transcription factor ATF4, and the UPR target gene
CHOP (see Table S3 for primers).
Consistent with the absence of intracellular accumula-
tion for the control COL4A2 cDNA, the common polymor-
phism, and the three likely nonpathogenic variants, we
did not detect ER stress or UPR activation for these variants
(Figure 5). In contrast, the pathogenic mutation and two2012
Figure 3. Col4a2 Mutant Mice Have Intracerebral Hemorrhages and Retention of COL4A1/A2 Heterotrimers within the ER
(A) Prussian Blue staining of brains from Col4a2þ/G646D mutant mice revealed multifocal ICHs in all mutant mice (n ¼ 5) and none in
control mice (C57BL/6J Col4a1þ/þ; Col4a2þ/þ, n ¼ 7, data not shown). The extent of the ICH appeared much less severe than ICH de-
tected in Col4a1þ/Dex40 mutant mice.
(B) To compare the severity of ICH between the twomutant lines, wemeasured the proportional area of ICH in brain sections at regularly
spaced intervals (mean5 SEM). Control (C57BL/6J) mice never had detectable ICH and ICHs in Col4a2þ/G646Dmutant mice were much
less severe than those observed in Col4a1þ/Dex40 mutant mice.
(C and D) Immunofluorescent labeling of COL4A1 or COL4A2 (rat H11 or rat H22 [1:200], respectively, with AlexaFluor488 anti-rat IgG
[1:500], Invitrogen; green) and the ERmarker PDI (mouse ID3 [1:500], Stressgen with AlexaFluor594 anti-mouse IgG [1:500], Invitrogen;
red) was performed in MEFs.38 MEFs were grown on glass coverslips, serum-deprived and treated with ascorbic acid (50 mg/ml) for 24 hr,
fixed with 4% paraformaldehyde, and permeabilized with 0.1% Triton in PBS. Cells were then mounted with Mowiol containing 40,
6-diamidino-2-phenylindole (DAPI) to label nuclei. Colabeling with PDI and anti-COL4A1 (C) or anti-COL4A2 (D) in control
(C57BL/6J Col4a1þ/þ; Col4a2þ/þ) cells showed considerable COL4A1/A2 labeling that did not colocalize with PDI and therefore was
not within the ER. In contrast, in Col4a1þ/Dex40 or Col4a2þ/G646D mutant cells all of the detectable COL4A1 and COL4A2 labeling
was colocalized with the ER marker, indicating ER retention of the COL4A1 and COL4A2 proteins. All animal experiments were
done with the approval of the UCSF institutional animal care and use committee.of the three putative mutations (COL4A2E1123G and
COL4A2Q1150K) triggered ER stress and UPR activation.
One putative mutation, COL4A2A1690T, had no evidence
of ER stress or UPR activation. This variant is within the
NC1 domain, and these data support the possibility thatThe Amemutations affecting the NC1 domain might have distinct
intracellular consequences compared to mutations affect-
ing the triple-helical domain. For example, mutations
within the triple-helix-forming domain could result in
misfolding of partially assembled heterotrimers, whereasrican Journal of Human Genetics 90, 91–101, January 13, 2012 97
Figure 4. Putative Human Mutations, COL4A2E1123G, COL4A2Q1150K, and COL4A2A1690T Encode Proteins that Are Retained within the
Endoplasmic Reticulum
Immunofluorescent labeling of COL4A2 (green; as described in Figure 3 legend) was performed in cells expressing controlCOL4A2 cDNA
or different COL4A2 variants. (A) In cells transfected with control COL4A2 cDNA, COL4A2 (green) is detected in the ER where it colo-
calized with PDI (red) and in post-ER vesicles (arrow). (D) In cells transfected with the pathogenic mutation COL4A2G1389R, all of the
COL4A2 labeling was perinuclear and colocalized with PDI consistent with ER retention. Similarly, in cells transfected with the three
putative mutations (B, C, and E), COL4A2 colocalized with PDI in a tight perinuclear pattern. (E) A nontransfected cell (red) that
does not express the COL4A2A1690T variant labeled with PDI and demonstrates a more disperse ER network compared to the transfected
cell expressing the putative mutation (yellow).mutation within the NC1 domain could interfere with the
initiation of heterotrimer assembly.
The current study provides strong evidence for involve-
ment of COL4A2 mutations in sporadic ICH. We rese-
quenced all coding sequences and flanking intervening
sequences for the entire COL4A2 gene, and we identified
three putative pathogenic mutations in four individuals
with ICH that were not present in at least 284 control
chromosomes. The putative mutations COL4A2E1123G,
COL4A2Q1150K, and COL4A2A1690T resulted in missense
changes in amino acids that are highly conserved across
species. Notably, none of these putative mutations are
glycine missense variants, which in COL4A1 are well estab-
lished to underlie severe, early-onset, and highly penetrant
cerebrovascular diseases. This could reflect an ascertain-
ment bias and perhaps nonglycine variants represent
alleles that present with milder disease later in life. It is
also possible that these variants become pathogenic later
in life as a consequence of interactions with other factors
that predispose to ICH. Although current in silico algo-
rithms are not ideal for predicting functional conse-
quences of COL4A2 variants, we showed that all three
putative mutations lead to decreased ratios of extracellular
to intracellular COL4A2 as a consequence of their
retention in the ER. Similarly, a mutation in the mouse or-
tholog, Col4a2G646D, caused intracellular retention of
COL4A1 and COL4A2 within the ER and ICH in the
mutant animals. Finally, two of the three putative muta-
tions that we identified also caused significant ER stress
and UPR activation. Both of these mutations occurred
within the triple-helix-forming domain and the sole puta-
tive mutation that did not lead to ER stress occurred within
the NCI domain.
ER stress has been proposed to be an important part of
the pathophysiology of collagen mutations. However,
because pathogenic COL4A1 and COL4A2 mutations
most often result in intracellular accumulation at the
expense of secretion, it is difficult to dissociate these two
consequences with respect to their relative contributions
to pathology. Although all three putative mutations98 The American Journal of Human Genetics 90, 91–101, January 13,showed increased ER retention of mutant proteins, the
inability to detect ER stress in one of the mutations might
suggest that UPR activation is not a necessary part of the
cellular pathophysiology. It is possible that the extent of,
and cellular response to, secretion differs in vivo compared
to our observations in vitro. Regardless, the identification
of putativeCOL4A2mutations in four out of 96 individuals
supports the hypothesis that COL4A2 mutations that per-
turb collagen biosynthesis can increase risk of sporadic
ICH in humans. In addition to the potential cytotoxic
effects of intracellular accumulation of mutant proteins,
the molecular pathway(s) could involve extracellular
insults (including a deficiency or the presence of abnormal
COL4A1/COL4A2 heterotrimers in the basement mem-
brane) that disrupt protein-protein interactions with other
basement membrane components, growth factors,23,25
and/or cell surface receptors. Evaluating these potential
cellular mechanisms with Col4a2mutant mice will inform
treatment or intervention options to prevent ICH in
patients with type IV collagen mutations.
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Figure 5. Putative Human Mutations, COL4A2E1123G and COL4A2Q1150K, Trigger ER Stress and Activation of the UPR
Quantitative RT-PCRs for ER stress and UPR markers were performed on cells stably transfected with control COL4A2 cDNA or different
COL4A2 variants that expressed similar levels of COL4A2, COL4A1, and collagen-binding chaperone HSP47 (top panels). For analysis,
cells were serum-deprived and treated with ascorbic acid (50 mg/ml) for 24 hr before being harvested. Total RNAs were isolated
from each clone with RNeasy mini kit (QIAGEN) and used for the generation of cDNA with iScript Supermix (Bio-Rad). RT-qPCRs
were performed with SsoFast EvaGreen supermix (Bio-Rad) on the equivalent of 20 ng of RNA. Presence of ER stress and UPR activation
were investigated with the expression levels of the ER chaperone BIP, two ER-resident transducers of the UPR PERK and ATF6, the
downstream transcription factor ATF4 and the UPR target gene CHOP (lower panel). The common variant COL4A2P718S and the
pathogenic mutation COL4A2G1389R were used as controls. Levels of expression are expressed relative to control (mean of four indepen-
dent clones 5 SEM). ER stress and UPR activation were detected in cells expressing the putative mutant COL4A2E1123G and
COL4A2Q1150K (*p < 0.05, **p < 0.01).Web Resources
The URLs for data presented herein are as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/
SIFT (Sorting Intolerant from Tolerant, version 2.0), http://sift.jcvi.
org/
PolyPhen (Polymorphism Phenotyping-2), http://genetics.bwh.
harvard.edu/pph/References
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